The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Conditions: Breast Cancer Interventions: Drug: Pyrotinib dose escalation; Drug: Pyrotinib dose normal Sponsors: The First Affiliated Hospital with Nanjing Medical University; Zhongda Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Jingjiang People ' s Hospital; Yancheng First People ' s Hospital; Affiliated Hospital of Jiangnan University; Affiliated Hospital of Nantong University; Anhui Provincial Cancer Hospital; Huai ' an First People ' s Hospital; The Affiliated Hospital of Xuzhou Medical University; Suzhou Municipal Hospital; Affiliated Hospital of Jiangsu University Recruiti...
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Conditions: Gastric Cancer; HER2-positive Gastric Cancer Interventions: Drug: Experimental; Drug: Control Sponsors: Gruppo Oncologico del Nord-Ovest Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Conditions: Breast Cancer; Tumor, Breast; Breast Tumor; Malignant Neoplasm of Breast; Mammary Cancer; Mammary Neoplasm; Mammary Neoplasms, Human; Neoplasm, Breast Interventions: Genetic: HTR2 T Cells; Genetic: HTR2 T Cells Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Conditions: Breast Cancer Interventions: Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-NeoB; Drug: Capecitabine Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan (T-DXd) with pyrotinib Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
Conditions: Breast Cancer Interventions: Diagnostic Test: Brain imaging; Diagnostic Test: Analysis of circulating tumor DNA; Behavioral: Testing Morbidities Index Sponsors: Sunnybrook Health Sciences Centre; Princess Margaret Hospital, Canada; MOUNT SINAI HOSPITAL; Trillium Health Partners Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study
Conditions: Advanced Breast Carcinoma Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
Conditions: Recurrent Ovarian Carcinoma Interventions: Drug: Dalpiciclib plus letrozole Sponsors: Fengzhi Feng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Conditions: Advanced Solid Tumor Interventions: Drug: FT825; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Bendamustine; Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab Sponsors: Fate Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
Conditions: Cervical Cancer; Endometrial Cancer; Ovarian Cancer; HER2 Expression Interventions: Other: no intervention Sponsors: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: irinotecan; Drug: IBI343; Drug: paclitaxel Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Conditions: Breast Cancer Stage IV Interventions: Drug: Sacituzumab Govitecan Sponsors: SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Conditions: Breast Neoplasm Female Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Inetetamab; Drug: Pyrotinib Sponsors: Wang Ouchen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
